Doctor profile · Federal record

Dr. Beata Rydzik, MD

Dermatology Physician (CMS: Dermatology) · Dermatology Physician · Clinical & Laboratory Dermatological Immunology Physician · Clinical & Laboratory Dermatological Immunology Physician · Procedural Dermatology Physician · Procedural Dermatology Physician · Dermatopathology Physician · Dermatopathology Physician · Portland, OR

  • NPI 1457357576
  • Accepts Medicare
  • MIPS 90.5 / 100 · 2023
  • 22 yrs in practice
  • Licensed in 2 states
  • Female
  • Group practice
  • No sanctions

Practice & contact

NPPES Updated May 11, 2026
Primary practice
9427 Sw Barnes RD, Suite 495
Portland, OR 972256652
(503) 297-3440
fax (503) 297-4584

Credentials & registration

NPPES · NUCC
NPI registered
June 2005 — 21 yrs on file
Profile last updated
June 13, 2012
Year of graduation
2004 — 22 yrs since
Specialty taxonomy
207N00000X — NUCC code
State licenses (2)
Oregon #MD25039 · Washington #MD00043352
Medicaid
OR #234458

Federal sanctions & exclusions

OIG LEIE Updated May 11, 2026

No sanctions, exclusions or revocations on file

Checked against OIG LEIE on NPI 1457357576. Last verified May 11, 2026.

Medicare procedures · 2023

Top services delivered

CMS Provider Utilization
Total services
5,604
Distinct HCPCS
10
Medicare allowed
$93,530
HCPCS Description Services Patients Avg allowed
J7345 Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg 4,800 15 $2
99214 Established patient office or other outpatient visit, 30-39 minutes 241 204 $132
17003 Destruction of precancer skin growth, 2-14 growths 166 29 $7
11102 Biopsy of related skin growth, first growth 112 101 $89
17110 Destruction of skin growth, 1-14 growths 54 52 $112
11103 Biopsy of related skin growth, each additional growth 53 32 $54
17000 Destruction of precancer skin growth, 1 growth 44 41 $47
96574 Application of light with debridement to destroy precancer skin growth 43 30 $307
J7308 Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) 27 15 $385
11301 Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm 18 16 $113

In context: peer comparison

Among 15 peers in this city , average services per provider: 168. This provider delivers 33× the peer median.

Open Payments

Industry payments received

CMS Open Payments
All-time total
$662
Transactions
15
Manufacturers
7
Payer (manufacturer) Industry Txns Amount
Novartis Pharmaceuticals Corporation 4 $166.40
Janssen Biotech, Inc. 5 $145.74
Regeneron Healthcare Solutions, Inc. 1 $130.93
E.R. Squibb & Sons, L.L.C. 2 $111.69
PFIZER INC. 1 $78.00
Arcutis Biotherapeutics, Inc. 1 $16.25
Amgen Inc. 1 $13.35

By nature of payment

Food and Beverage
$597
Education
$65

Medicare Part D · 2023

Top prescriptions

CMS Part D Prescriber
Total claims
622
Patients
373
Total drug cost
$22,891
Drug Type Claims Patients Total cost
Clobetasol Propionate Generic 85 59 $3,847
Doxycycline Hyclate Generic 85 27 $2,867
Minoxidil Generic 62 20 $629
Mupirocin Generic 61 50 $554
Fluorouracil Generic 55 54 $4,999
Metronidazole Generic 42 23 $2,742
Finasteride Generic 41 0 $494
Ciclopirox (Ciclopirox Olamine) Brand 40 30 $1,421
Ketoconazole Generic 38 30 $1,090
Triamcinolone Acetonide Generic 32 28 $299

Frequently asked questions

Auto-generated from federal data
What is Dr. Beata Rydzik's medical specialty?
Dr. Beata Rydzik practices Dermatology Physician in Portland, OR.
Where does Dr. Beata Rydzik practice?
Dr. Beata Rydzik practices at 9427 Sw Barnes RD, Portland, OR 972256652. Office phone: 5032973440.
What is Dr. Beata Rydzik's NPI?
Dr. Beata Rydzik's National Provider Identifier (NPI) is 1457357576, issued by NPPES.
Does Dr. Beata Rydzik accept Medicare assignment?
Yes. Dr. Beata Rydzik accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Beata Rydzik commonly perform?
Top Medicare-reported procedures in 2023: Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg (HCPCS J7345); Established patient office or other outpatient visit (HCPCS 99214); Destruction of precancer skin growth, 2-14 growths (HCPCS 17003). Source: CMS Medicare Physician & Other Practitioners file.